Organovo Holdings (Seite 114)

[Popeye82]

Ich könnte mir hier einen Einstieg künftig noch sehr gut vorstellen. Jetzt aber nicht.
Kann ruhig nochma ordentlich abschmieren, von mir aus.

Organovo Provides Guidance on Retail Investor Conference - Mar 28, 2014
http://app.quotemedia.com/quotetools/newsStoryPopup.go?story…

"SAN DIEGO, March 28, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today provided guidance on topics to be discussed at an upcoming Retail Investor Conference on April 10, 2014.

Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Thursday, April 10, 2014 at 12:00pm ET, and investors can directly participate in this live, interactive online event. Investors will be invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." Organovo has regularly updated its online presentation at retailinvestorconferences.com, and the company maintains its most recent investor conference for on demand viewing at any time. The most recent version can be viewed now by visiting retailinvestorconferences.com. Because the company maintains 24/7 access to this extensive presentation on its technology and business, it has at times declined to have shorter presentations with a subset of the same information presented to be webcast or recorded, such as the 15 minute short form presentation at the Alliance for Regenerative Medicine investor conference on March 26, 2014. All information provided at that conference, and more, is found in the current on-demand presentation.


At the upcoming conference on April 10, Organovo will provide information on several topics, including:

- KOL update: guidance on expectations and timelines for key opinion leader (KOL) evaluation of Organovo's 3D Liver tissue;

- Cash burn and R&D spending: Review of the company's cash position and expectations of future spending;

- Update on progress of bioprinted breast cancer models: New results from Organovo's bioprinted breast cancer models are expected to be released at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 5-9 in San Diego, CA. Mr. Murphy will review the results on the live investor conference on April 10;

- Advantages of NovoGen 3D Bioprinting versus currently available methods and technologies: Organovo will cover the advantages of its NovoGen 3D Bioprinting to achieve breakthroughs in the creation of living tissue, including up to date data from its 3D Liver product. Based on the performance of the liver to date, which will be reviewed at the conference, the company believes its human liver model currently in development has the opportunity to redefine the category of in vitro assays as being fully human; multicellular; three dimensional in size, shape, and substance; and consistent in form and function with a native tissue sample. It also believes this set of attributes is unique and umatched by current products and technologies, none of which use any form of bioprinting today.


DATE: April 10, 2014
TIME: 12:00 PM ET

If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for at least 90 days. It is recommended that investors pre-register to save time and receive event updates.

To watch Organovo's most recent investor presentation on demand, please follow these instructions:

LINK: www.retailinvestorconferences.com > click on red "register / watch event now" button
Register or login
Go to "Auditorium"
Select "Watch this month's presentations"
(December event)
Scroll down and select "Organovo"


About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com. "

[Popeye82]

Organovo "Celebrates Economist Technology Quarterly Coverage" - Mar 12, 2014
http://ir.organovo.com/news/press-releases/press-releases-de…

"SAN DIEGO, March 12, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today celebrated a profile of the company and the 3D bioprinting space as the cover story in the Economist's Technology Quarterly.

Keith Murphy, chairman and chief executive officer of Organovo, commented that "Organovo is proud to continue to receive insightful coverage in top business and financial news outlets. We appreciate the recognition as a top tier biotechnology company showing leadership in an emerging and important space."


In its coverage, the Economist's Technology Quarterly describes:

- the role of Organovo Scientific Founder Prof. Gabor Forgacs in foundational work in the bioprinting field;

- the potential of Organovo's bioprinted 3D Liver tissues to improve pharmaceutical toxicity testing;

- Organovo's technology advantage in being able to make 100% cellular tissues; and

- Organovo's work in early animal studies to create simple tissues for direct surgical implantation to treat patients; and other details of the company's strategy, technology, and operations.


In putting together their detailed coverage, the Economist's Technology Quarterly had a scientific writer visit the company, receive access to the company's facilities, and review and interview many others in the space. Organovo worked directly with this writer over the course of two months to provide information for the piece.

Organovo has continued to receive coverage in important news outlets, such as Fox Business News and Bloomberg News in February 2014, and important customer-facing outlets such as Genetic Engineering and Biotechnology News, and Medical Device and Diagnostic Industry in January 2014. We are further pleased to announce that our CEO, Keith Murphy, was recognized as one of 50 fascinating people in technology by Networkworld, which recognizes innovative and inspirational work in technology.

Organovo is also pleased to be named a 2014 Award Finalist by the internationally renowned Edison Awards™. The distinguished awards, inspired by Thomas Edison's persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy. The Edison Awards Steering Committee and more than 3,000 professionals from the fields of product development, design, engineering, science, marketing and education have voted the NovoTissue® Human Liver Model, as a 2014 Edison Award Finalist. We look forward to the announcement of the winners on April 30.

As regards certain other information outlets, Organovo continues to caution investors regarding the content of certain reports targeting existing and potential investors in its common stock, especially on certain internet sites. Organovo, like many other innovative technology companies, has been the subject of various articles on certain investor websites or from independent researchers that contain significant factual errors. The content of these reports can be submitted by independent authors, without any specific qualifications, experience or expertise required. In fact, most sites do little or no fact checking, provide little to no editorial oversight, and provide limited or no mechanisms for correction of factual errors.

While some errors may be unintentional or simply sloppy, on some occasions it is possible that some authors may be following a "Short and Distort" strategy, where they purposefully create a negative picture after taking a short position. Organovo cautions investors to watch out for some telltale signs of a Short and Distort article or report, including articles that:

- Use phrases like "Trading Warning" or "Urgent" explicitly intended to cause fear and based on no new publicly released information about the Company;

- Be written by a person with a short position and focused on negative details – with little balanced discussion of positives and negatives about the Company;

- Be written by an individual with no known track record in investing or equity analysis, no known scientific qualifications, or in fact no affiliation with any entity known to the investor which could provide any confidence in his or her qualifications;

- Pretend to have a greater understanding of Organovo's SEC filings, especially in regards to potential future financings or share registrations, and proceed to interpret them selectively in unbalanced ways;

- Be excessively focused on Organovo's path to becoming public through reverse merger, ignoring the fact that the company's subsequent fully underwritten secondary offering at >$40M, with full investment bank diligence, removes consideration of Organovo under the typical reverse merger listing standards by both NYSE and NASDAQ;

- Overemphasize Organovo's lack of current revenue as somehow indicative of the promise of its future products rather than its status as a development stage biotechnology company;

- Highlight and demonize the potential for future financing instead of recognizing it as beneficial for shareholders under the right conditions;

- Focus on Organovo's institutional investor holdings without noting that these holdings have grown significantly since early 2013, or without noting that the company conducted a financing round in August 2013 that consisted nearly entirely of seasoned institutional biotech investment funds;

- Cherry pick negative details for past companies where Organovo executives played roles, without discussion of the multiple successful roles the same executives have played in companies acquired for nine-figure sums, or their participation in product development for products and product lines currently generating revenue in the billions of dollars;

- Compare Organovo's public company executive salaries, including non-founders, to private startup founders for earlier stage companies rather than peer companies;

- Denigrate Organovo's partnerships or doubt their existence – when review of all of the company's relationships with these groups, including reviewing full contract detail and conducting direct discussions with the partner companies, is performed by investment bankers as part of diligence for underwritten deals such as Organovo's sale of securities on August 1, 2013;

- Refer to an EnvisionTEC Bioplotter that prints biomaterials suitable for scaffolds as a "bioprinter", and compare it to bioprinting instruments designed to create living human tissue from cellular inks; or

- Refer to other Organovo short thesis article sources as if they were excellent points of reference (e.g., cross referencing other writers on the same website, referring to Nanalyze, or even pointing to the personally maintained webpage of an "online commentator" whose sole previous qualification and experience in analysis is literally writing comments on websites).


The company would like to help investors judge such content appropriately, and point out the risks of encountering false information. The company would like to stress that in providing information in regards to such sites or reports to investors, it is not claiming that all articles with a negative connotation are false. In addition, not every positive article regarding the company may be balanced with the potential risks and uncertainties the company faces. For these reasons, Organovo strongly encourages all investors to regularly review and focus on its filings with the Securities and Exchange Commission and its press releases for information regarding the Company, including the risk language in such filings.

The company reminds investors to review its SEC filings in regards to executive equity sales plans, which it has provided updates on from time to time in Current Reports on Form 8-K. The most recent relevant filing can be found here.

The company reminds investors that its FAQ pages are regularly updated and an excellent source of information. Click here to read the current FAQ.

In addition, the company regularly engages investors in public forums to answer questions and discuss the sorts of issues of concern to investors. Please watch Organovo's website for details on the next conference, or sign up for company alerts here.


About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com. "

[PhaseDrei]

Antwort auf Beitrag Nr.: 46.550.291 von Mika_1 am 02.03.14 15:42:49

Hallo,

Dies ist aus meiner Sicht der beste Artikel zum Thema Bioprinting, den ich bis heute gelesen habe:
Informativ und neutral

http://www.economist.com/news/technology-quarterly/21598322-…

Schöne Wochenendlektüre

Gruß, Phase

[Mika_1]

Hi Leute,

gibt es eigentlich mittlerweile weitere Mitbewerber im BioPrint-Bereich, die an der Börse notiert sind?
Kenne "Harvard Apparatus Regenerative Technology" und "Rainbow BioSciences bzw.Rainbow Coral Corp.".

Viele Grüße!
Mika

[PhaseDrei]

Antwort auf Beitrag Nr.: 46.427.624 von rechnerhand am 11.02.14 20:51:11

hallo,

Wikipedia

http://de.wikipedia.org/wiki/Bioprinter

Bioprinting wird hoffähig, und Organovo ist der Goldstandard

bei mir macht sich das Gefühl breit, dass es bald wieder richtig los geht

Wir haben ja auch lange genug in der Nähe der MA 50 herumgetänzelt

Gruß, Phase

[rechnerhand]

The next step: 3D printing the human body

http://www.telegraph.co.uk/technology/news/10629531/The-next…

[schnorps01]

aus Seeking Alpha....

Organovo Could Benefit From 3D Systems, Stratasys Flight Feb. 10, 2014 5:42 AM ET | About: ONVO, Includes: DDD, XONE by: LastFinancier Disclosure: I am long ONVO. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. (More...)
Organovo (ONVO) will be one of the beneficiaries of an enormous outflow of capital from broader 3D printing names and into specialty companies that focus on a viable niche. As 3D Systems (DDD) guided earlier last week, the Company will not meet its guidance on FY2013 earnings. ExOne (XONE) said in January that a longer-than-expected sales cycle would bring revenues in below expectations for 2013, also. Altogether, the 3 largest 3D printing companies (by revenue) will report an aggregate of $1.2B in sales for fiscal 2013 - a rounding error on 0.1% of global manufacturing sales. Organovo is expected to remain pre-commercial until the end of 2014, meaning revenues will not be significant until that time.

Company
Revenue (in millions $), est.

Stratasys
670

3D Systems
513

ExOne
40


The reason broader 3D printing companies will continue to be a non-factor in global manufacturing is that input prices will not fall fast enough to make 3d printers competitive in consumer markets and large-scale industrial applications. 3D Systems echoed this in their recent press release:

[PhaseDrei]

Antwort auf Beitrag Nr.: 46.367.491 von PhaseDrei am 03.02.14 17:20:33

Hallo,

[urlhttp://organovo.q4cdn.com/ed1f64e9-f25c-4729-b63c-cf3579373951.pdf?noexit=true][/url]

Mal sehen, wie der Markt reagiert

Gruß, Phase

[PhaseDrei]

Antwort auf Beitrag Nr.: 46.366.917 von mecknes1 am 03.02.14 16:31:02

Hallo,

der Januar war i.A sehr schwach und die gesamten Märkte befinden sich derzeit in keiner guten Verfassung;

hinzu kommt momentan die stark ausgeprägte Schwäche im 3D-Sektor

Die Meilensteinmeldung der vergangenen Woche hätte für ONVO in den Euphoriephasen sicher zu einem Plus in der Größenordnung von 30-40 % geführt;

in diesem schwachen Umfeld ist der kurze Anstieg quasi gesamt wieder verpufft;

Hinzu kommen in dieser Woche die Quartalszahlen von ONVO, die keine positive Überraschung bedeuten werden;

alles in allem agiere ich zur Zeit sehr vorsichtig;
wenn ich hier wieder einsteige, dann nur nach deutlichem Rutsch und nur kurzfristig!

Langfristig gesehen wird ONVO seinen Weg gehen!

hmm mal schauen-
zur Zeit wird die 9 zum wiederholten Male ins Visier genommen

Gruß, Phase

[mecknes1]

der gesamt markt ist am boden, und die 3D druck firmen sind heute noch stärker im minus.